The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines

Lung Cancer

Volumn 78, Issue 3, 2012, Pages 193-200

  Shen, Lan ^a   Li, Ziming ^a   Shen, Shengping ^a   Niu, Xiaomin ^a   Yu, Yongfeng ^a   Li, Zonghai ^b   Liao, Meilin ^a   Chen, Zhiwei ^a   Lu, Shun ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anastrozole; EGFR; ER; Gefitinib; Interaction; Lung cancer

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GEFITINIB; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BRONCHUS; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NITRILES; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIAZOLES;

EID: 84868300169     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.08.012     Document Type: Article

References (30)

1. American Cancer Society Surveillance Research Cancer facts and figures 2004 2004, American Cancer Society, Atlanta (GA), p. 1-60.
2. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor mechanisms of activation and signalling. Exp Cell Res 2003, 284(1):31-53.
3. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372(9652):1809-1818.
4. Mollerup S., Jørgensen K., Berge G., Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37(2):153-159.
5. Niikawa H., Suzuki T., Miki Y., Suzuki S., Nagasaki S., Akahira J., et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008, 14(14):4417-4426.
6. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003, 17(3):309-317.
7. Abe K., Miki Y., Ono K., Mori M., Kakinuma H., Kou Y., et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 2010, 41(2):190-198.
8. Miki Y., Suzuki T., Abe K., Suzuki S., Niikawa H., Iida S., et al. Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res 2010, 70(16):6659-6669.
9. Verma M.K., Miki Y., Sasano H. Aromatase in human lung carcinoma. Steroids 2011, 76(8):759-764.
10. Mah V., Seligson D.B., Li A., Márquez D.C., Wistuba I.I., Elshimali Y., et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 2007, 67(21):10484-10490.
11. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11(12):1135-1141.
12. Weinberg O.K., Marquez-Garban D.C., Fishbein M.C., Goodglick L., Garban H.J., Dubinett S.M., et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005, 65(24):11287-11291.
13. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006, 24(1):59-63.
14. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62(7):2141-2150.
15. Nose N., Sugio K., Oyama T., Nozoe T., Uramoto H., Iwata T., et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009, 27(3):411-417.
16. Omoto Y., Kobayashi Y., Nishida K., Tsuchiya E., Eguchi H., Nakagawa K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001, 285(2):340-347.
17. Björnström L., Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005, 19(4):833-842.
18. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005, 19(8):1951-1959.
19. Kawai H., Ishii A., Washiya K., Konno T., Kon H., Yamaya C., et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005, 11(14):5084-5089.
20. L858R non-small-cell lung cancer cell line H3255. Cancer Res 2004, 64:7241-7244.
21. Li Z., Zhou S., Zhang L., Su C., Hang J., Zhao Y., et al. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol 2011, 28(2):572-577.
22. Song R.X., Santen R.J. Membrane initiated estrogen signaling in breast cancer. Biol Reprod 2006, 75(1):9-16.
23. Filardo E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002, 80(2):231-238.
24. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, gpr30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000, 14(10):1649-1660.
25. Razandi M., Pedram A., Park S.T., Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003, 278(4):2701-2712.
26. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65(4):1459-1470.
27. Shen H., Yuan Y., Sun J., Gao W., Shu Y.Q. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 2010, 64(2):88-92.
28. Márquez-Garbán D.C., Chen H.W., Fishbein M.C., Goodglick L., Pietras R.J. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007, 72(2):135-143.
29. Traynor A.M., Schiller J.H., Stabile L.P., Kolesar J.M., Eickhoff J.C., Dacic S., et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009, 64(1):51-59.
30. Garon E.B., Dubinett S.M., Hosmer W., Reckamp K.L., Kabbinavar F.F., Goodglick L., et al. Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15s). [suppl; abstr TPS295].